In This Issue  by unknown
Chemistry & Biology
In This IssueTargeting Sec Translocase Traffic Jam with Motor Inhibitors
PAGE 685
New antibiotic targets are currently being explored in the search for new therapies to combat infections caused by multidrug
resistant bacteria. In this review, Segers and Anne´ provide an overview of research efforts on the discovery of small-molecule
inhibitors of SecA, a central component of the bacterial secretory pathway. Recent advances regarding the structure and
function of SecA and their potential impact on antibacterial drug discovery are discussed, suggesting that although the
SecA active site is not an ideal drug target, it might be possible to develop inhibitors to disrupt the interaction of SecA
with its various protein ligands.In Situ Kinase Profiling
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Here, Patricelli et al. show that profiling of native kinases in cell or tissue lysates using active-site-directed
probes enables comprehensive determination of inhibitor potency and selectivity in a species-indepen-
dent manner. They observe strong correlation between probe-based IC50 values and in vivo efficacy
for several kinase inhibitors and demonstrate the predictive power of probe-based studies. Moreover,
differences in inhibitor potency for recombinant andnative enzymesarepresented that highlight the valueof native kinase profiling in drug discovery efforts, which together with observations of inhibitor-induced kinase activation,
further demonstrate the value of kinase probes directed to active sites.Plasmodium: Welcome to the SUMO Game
PAGE 711
Small ubiquitin-related modifier (SUMO) is implicated in the regulation of numerous biological processes, including transcrip-
tion, protein localization, and cell cycle control. In Plasmodium falciparum, the parasite that causes human malaria, the func-
tional significance of SUMO modification is unclear. Here, Ponder et al. describe the expression and characterization of an
active SUMO regulatory protease of P. falciparum, PfSENP1. Subsequent screening of a small molecule library identified
a compound that inhibited PfSENP1 and induced parasite death, indicating that PfSENP1 may be a viable drug target. These
inhibitors are likely to be valuable tools for studying SUMOylation in parasites and other eukaryotic systems.New Probes for SENPs
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A commonly used yet poorly understood mechanism for posttranslation regulation of proteins is the addition of a small ubiq-
uitin-like modifer (SUMO) protein tag. Recent efforts have begun to uncover the repertoire of proteins that are regulated
through SUMOylation. However, SUMO modification is dynamic, making it difficult to monitor the temporal aspects of this
posttranslational process. Here, Albrow et al. describe the design and synthesis of small molecule inhibitors of the human
SUMO-specific proteases (SENPs) that can be used to block SUMO removal from substrates, thus allowing more compre-
hensive studies of SUMOylation pathways in the cell.Rhodopsin Photoactivation: Less (Isomerization) Than Meets the Eye
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Light absorbed by the N-retinylidene chromophore of the visual receptor rhodopsin triggers electron motion along the chro-
mophore. The conserved, highly polarizable amino acid residues surrounding the chromophore capture light absorption by
translating the electron motion into protein conformational change essential for rhodopsin activation. Using a rhodopsin
from Chlamydomonas, Foster el al. show that completely nonisomerizable chromophores retain full photoactivation of
rhodopsin. This electronic activationmechanism is applicable to all rhodopsins, as they all have N-retinylidene chromophores
that are located in a trough of highly polarizable amino acid residues. Notably, related GPCRs for pharmaceutical ligands
share a similar electron motion mechanism.TOP(2) Inhibition: New Approach to Cancer Therapy
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Identifying themolecular target of uncharacterized bioactive small molecules is a crucial step in
drug development and chemical genetic studies. Using their recently developed proteomic
profiling approach, Kawatani et al. identify the target of BNS-22, which has antiproliferative
activity against human cancer cells, as DNA topoisomerase II (TOP2) and show that it acts
as a catalytic inhibitor in a cell system. This study identified a new structural class of TOP2
inhibitors that can be used to treat cancers with high levels of DNA repair, which currently
compromise the therapeutic effects of DNA-damaging agents.Chemistry & Biology 18, June 24, 2011 ª2011 Elsevier Ltd All rights reserved v
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Oxidative stress is a recognized mediator of many neurological conditions including stroke, spinal
cord injury, Parkinson’s disease, and Alzheimer’s disease, but there is also growing recognition
that ‘‘oxidative stress’’ cannot be therapeutically defeated with a single antioxidant scavenger. An
alternative approach is to induceabroad rangeof genescapable of neutralizing thedeleterious effects
of many oxidants. Here, Smirnova et al. describe a novel reporter assay, ideally suited for high
throughput screening, to identify direct activators of Nrf-2 transcription factor, a master regulator of
the antioxidant defense response, which allowed them to find nonoxidant activators.Role of Protein Homeostasis in Gaucher’s Disease
PAGE 766
Lysosomal storage diseases are caused by aberrant accumulation of metabolites in the lysosomes. Gaucher’s disease is the
most common among these diseases and is characterized by mutations in the gene encoding for lysosomal glucocerebro-
sidase (GC) that destabilize native folding and lead to rapid degradation. Here, Wang et al. demonstrate that treatment of
diseased fibroblasts with the L-type Ca2+ channel blocker lacidipine results in increased folding, cellular trafficking, and
activity of mutated GC variants. They propose a novel mechanism for protein homeostasis that combines modulation of
cellular folding and Ca2+ homeostasis, while at the same time protecting from induction of apoptosis.Targeting SOC in Huntington’s Disease
PAGE 777
Huntington’s disease (HD) is a neurodegenerative disorder caused by a polyglutamine expansion within the Huntingtin (Htt)
protein. Using a phenotypic screen,Wu et al. identified a class of quinazoline-derived compounds that delayed progression of
a motor phenotype in transgenic Drosophila HD flies. They found that these compounds act by inhibiting store-operated
calcium entry (SOC) pathway in HD neurons. The authors conclude that the neuronal SOC pathway constitutes a novel target
for HD treatment and that the identified compounds represent a novel class of therapeutic agents for treatment of HD and
possibly other neurodegenerative disorders.Anamorsin and Mia40: Trapped in the Mitochondria Together
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Here, Banci et al. structurally characterize human anamorsin, implicated in cytosolic Fe/S cluster biogenesis, and show that it
binds a [2Fe2S] cluster. Anamorsin is found to be a novel substrate of Mia40, an oxidoreductase involved in protein trapping
in the mitochondrial intermembrane space (IMS). It catalyzes the formation of disulfides in a twin CX2C motif of anamorsin.
Import of anamorsin in the IMS, together with the observation of an intermolecular disulfide-bonded Mia40-anamorsin inter-
mediate, suggest that these interactions exist in mitochondria and that anamorsin plays a role in the cytosolic Fe/S cluster
biogenesis, once it is imported in the IMS.Measuring In Vivo Protein Half-Life
PAGE 805
The rate of turnover of proteins critically influencesmany biological functions, yet methods have so far been
lacking to assess this parameter in vivo. Here, Bojkowska et al. demonstrate that pulse chase labeling of
proteins fused to a SNAP-tag, a mutant of human O6-alkylguanine-DNA alkyltransferase, can be exploited
to measure the in vivo half-life of proteins in living animals, thereby opening new perspectives for studying
in vivo protein function., June 24, 2011 ª2011 Elsevier Ltd All rights reserved
